Good day ladies and gentlemen and welcome to the Consensus Q3 2023 Earnings Call. My name is Paul and I will be the operator assisting you today. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. On this call from Consensus will be Scott Turicchi, CEO; John Nebergall, COO; Jim Malone, CFO; and Adam Varon, Senior Vice President of Finance. I will now turn the call over to Adam Varon, Senior Vice President of Finance at Consensus. Thank you. You may begin.

Good afternoon and welcome to the Consensus investor call to discuss our Q3 2023 financial results, other key information, and 2023 guidance. Joining me today are Scott Turicchi, CEO; John Nebergall, COO; and Jim Malone, CFO. The earnings call will begin with Scott providing opening remarks, John will give you an update on our operational progress since our Q2 investor call, and then Jim will discuss the Q3 2023 financial results and 2023 guidance. After we finish our prepared remarks, we will conduct a Q&A session. At that time, the operator will instruct you on the procedures for asking your question. Before we begin our prepared remarks, allow me to direct you to the Safe Harbor language on Slide 2. As you know this call and the webcast will include forward-looking statements. Such statements may involve risks and uncertainties that would cause actual results to differ materially from the anticipated results. Some of those risks and uncertainties include but are not limited to the risk factors outlined on Slide 3 that we have disclosed in our 10-K SEC filing as well as a summary of those risk factors that we have included as part of the slide show for the webcast. We refer you to discussions in those documents regarding Safe Harbor language as well as forward-looking statements. Now, let me turn the call over to Scott.

Thank you, Adam. It's now been two years since our spin, and I would like to make some brief comments as we look back over these past two years. As you know, we spun with a go-to-market focus and product roadmap aimed at the healthcare sector. We have made substantial investments and strides in this space, with more than half of our corporate revenue now coming from the healthcare sector. However, we have also seen inflation and a tight labor market impact revenue growth in this piece of our business. In fact, in the past two quarters, we have seen overall corporate revenue growth of approximately 3%, down from approximately 13% in Q3 of 2022. This was driven by a slowdown in revenue generation from our healthcare customers due to stable usage, slower sign-ups, and a slow ramp of our larger customers. Until there is a substantial relief in the labor markets, we expect these trends to continue. As we look to next year, with continuing uncertainty in both the economy and the labor markets, we'll be focusing our attention on EBITDA and free cash flow generation. As a result, we will reduce our capitalized investments from the level of the past two years while still investing in the business at a rate higher than prior to the spin. The record cash balances of $156 million in future free cash flow will be dedicated to repurchasing our equity and debt securities. Now that we have cleared the two-year mark from the spin, we are able to repurchase debt, and as a result, the Board has authorized a $300 million repurchase program over the next three years. This program covers both the 6% notes that mature in October of 2026 as well as the 6.5% notes due in October of 2028. These repurchases can take a variety of forms, and we'll be opportunistic, similar in manner to our existing stock repurchase program. While we are early in the budgeting process, I would expect negligible overall revenue growth in 2024, with a continuing decline in SoHo revenues offset by mid-single-digit growth in our Corporate channel. I would also expect greater growth in our EBITDA than in our revenue. We will be providing full-year 2024 guidance on our Q4 earnings call to be held in February. While our revenues were disappointing in the quarter, there were several factors that affected the results. Within the SoHo channel, we cut a meaningful amount of marketing spend on questionable profitability channels. I would also note that as we discussed last quarter, the price change to that base is complete. On the Corporate side, in addition to the headwinds experienced in the healthcare sector, we also completed the migration of our FAXBOX customer base but did incur customer attrition in the process. This was a legacy system that needed to be retired, notwithstanding the customer and revenue loss. On the bright side, our EBITDA margin remained strong at 52.5%, the midpoint of our range. And coupled with interest income on our cash balances and a lower share count, produced year-over-year growth in EPS. In addition, we generated a record $50 million of free cash flow for a full fiscal quarter post-spin and more importantly, $83 million for the nine months. As usual, there are timing differences in the payment of estimated taxes and cash collections of receivables. Also, as we've noted before, due to our debt structure and interest payments, we generate most of our free cash flow in quarters one and three. I will now turn the call over to John for more detail on the quarter.

Hi, thank you, Scott. As we mentioned on the last call, we held a meeting with the ECFax partners to discuss tactics for accelerating the rollout. The talks were substantive, and all partners agreed that an acceleration of the overall program in 2024 would be a mutual goal. In that context, we are actively working on acceleration options and are making progress on the overall plan. While not final, we are encouraged by the direction and anticipate a favorable schedule for next year. Now, that said, we have seen the hurdles that can be encountered in a project of this scope and are going to be cautious in forecasting any revenue expected from the program next year. As for the current state of the implementation, we have increased the number of facilities using ECFax, and while the pure number of facilities is an improvement, the level of usage per facility varies and not every location has been fully implemented. As we have discussed, there are nearly 30 other government agencies in the pipeline, and while progress is being made, the threat of a government shutdown earlier this quarter and the upcoming holiday season have slowed the speed of discussions. We do not expect any measurable progress on this front until sometime in 2024. On the Clarity front, we are in the process of implementing our first Clarity PA client, who signed last July. Clarity PA is a specifically engineered version of Clarity aimed at the problem of prior authorization workflow. As Scott has mentioned, the slow progress in closing the deal and implementing the customers are fully on display here. The deal took 15 months to close and will likely require an additional 12 months to implement. In the AI market, this is a typical timeframe, and is what we can anticipate with each subsequent prospect engagement. Separately, we have launched the Clarity CD product, tuned for Clinical Documentation Administration, and built the pipeline of interest. Our sales team is progressing through those opportunities and serious discussions are underway. On the sales front for the quarter, Q3 bookings came in at $6.4 million, which was a welcome improvement from both Q1 and Q2 results. Historically, Q3 has been the best month seasonally for sales, and it appears to be holding true this year. While this result is a welcome improvement sequentially, it is still under last year's Q3 result, and year-to-date overall 2023 bookings are still lagging 20% behind our 2022 pace. Our advanced product sales came in just short of $1 million, and while that was an improvement over Q2, that also still lags behind the 2022 pace. We've also continued our aggressive pursuit of harvesting healthcare accounts from the SoHo base into a more expensive corporate product. For the past several quarters, we have been successfully upgrading more than 1,000 SoHo accounts per quarter into a corporate product, and this quarter is no exception, with about 1,300 customers upgraded from SoHo. While each upgrade is a positive increase in revenue, it does come with a negative impact in a couple of key metrics that are important to note. First, these customers tend to be on the extreme low end of our corporate average revenue per account or ARPA range, impacting our overall corporate ARPA with downward pressure. Second, the process for changing an account from SoHo to corporate includes cancellation of the SoHo account. This process then creates an unfavorable impact on SoHo churn, as our system calculates the cancellation as a churned account. So as you assess our operating metrics, be aware that our upgrade program has those impacts. In the quarter, we were able to close two large hospital system deals, with a combined 60-plus hospitals, over 400 clinics, and more than 100 skilled nursing facilities. Due to their level of complexity, we anticipate that implementation will take most if not all of 2024. As you will recall from our discussion about the go-to-market realignment earlier this year, we established the e-commerce group for all web-based self-service sales. This group includes our traditional SOHO revenue stream and has been expanded to encompass upmarket sales to the SMB market. This quarter, the SOHO market saw further moderation of the churn that we saw last year due to our price increase rollout. Churn for the quarter came in just under 3.5%, a nice improvement from last year's Q3 result. Now, as mentioned earlier, that number includes the 1,300 accounts that we upgraded to Corporate. As we discussed last call, we continue to see the pace of new adds fall under pre-pandemic levels. As we've also said on our last call, the expectation is that this trend will be the new normal in SOHO as we have made the decision to pull back spending in areas of SOHO that we found to have questionable profitability and we'll continue to scrutinize our marketing spend to ensure high returns for the business. This quarter, we launched an e-commerce product targeting SMB customers. Traditionally, we had used our inside sales team to sell inbound web opportunities and these form-fill customers would be assisted by a live sales rep. The release of this eFax Protect product marks our first entry into the self-service sales approach for corporate. Finally, on the product front, as mentioned earlier, we successfully released Clarity CD and we have also successfully completed the Jsign HITRUST audit.

Thank you, John, and good afternoon, everyone. Let's start with our corporate business results. Q3 2023 revenue was $50.4 million, an increase of $1.5 million or 3% over the prior year comparable period, versus growth of 13% from Q3 2021 to Q3 2022. The corporate revenue growth slowed to 3% from 13% in Q3 2022 due to an increased number of customers at lower ops as our larger clients remain slow in both their decision cycles and implementation. Corporate ARPA at $312 was down $36 or 10.5% from the prior year, attributable to the mix of paid adds at a lower ARPA, including SOHO accounts moving to corporate. However, it was similar to the ARPA as we experienced in Q2. Monthly churn improved 20 basis points to 1.5% over the prior year, delivering a trailing 12-month revenue retention of 100%. Moving to SOHO results, Q3 2023 revenue of $40.1 million, a decrease of $2.7 million or 6.2% over the prior comparable period. This decrease was driven by an anticipated decline in our base offset by the impact of price increases in the period. This was the hardest comparable as the price increase had substantial effect in Q3 2022, but there had not yet been a meaningful increase in churn. In addition, as Scott noted, we cut marketing spend where the lifetime value to customer acquisition cost was marginally profitable. The ARPA of $15.31 increased by $0.89 or approximately 6% year-over-year, benefiting from the price increase. Churn declined 10 basis points to 3.5% compared to the prior period and pre-price increase levels. Notwithstanding the above 6.2% revenue decline in the quarter, the full-year SoHo revenue decline is benefiting from the first half performance of a negative 3% and expect it to improve, ending the year within our 2% to 4% guidance range. Moving to Q3 consolidated results, revenue of $90.6 million is a decrease of $1.2 million or 1.3% over Q3 2022. Adjusted EBITDA of $47.5 million was a decrease of $1.6 million over Q3 2022 or 3.2%, delivering a 52.5% margin. The main drivers are the revenue fall through mentioned above, the plan employing costs, timing of bad debt expenses, while managing costs to keep EBITDA margins within the 50% to 55% guidance expectations. The Q3 2023 non-GAAP tax rate and share count was 19.1% and 19.7 million shares, respectively. Note we repurchased 152,000 shares in the quarter and approximately 500,000 shares year-to-date. Adjusted non-GAAP net income $29.7 million increased $1.1 million or 3.7% driven by the benefits of interest income of $1.5 million, non-cash revaluation of intercompany accounts of $0.7 million and a lower effective tax rate. Non-GAAP EPS of $1.51 was better than the prior comparable year by 5.6% or $0.08. We continue to build our cash position ending the quarter with a record $156 million in cash and cash equivalents, which is sufficient to fund our operations and debt. Q3 was a record post-spin full fiscal quarter free cash flow of $49.9 million. Turning to guidance, Q4 2023 guidance range is as follows: Revenues between $87.5 million and $90.5 million, with $89 million at midpoint. Adjusted non-GAAP EBITDA between $46.3 million and $48.2 million, with $47.4 million at midpoint. Adjusted non-GAAP EPS at $1.15 to $1.19, with $1.17 at midpoint. For the full-year guidance, revenues between $362 million and $365 million, with $364 million at midpoint. Adjusted non-GAAP EBITDA between $186 million and $188 million, with $187 million at the midpoint. Adjusted non-GAAP EPS at $5.13 to $5.17, with $5.15 at the midpoint. We're planning to file our Q3 2023 10-Q at market close today, November 9. That concludes my formal comments. I'd like to turn the call back to Scott for some final remarks before we move to the Q&A section. Thank you.

Thank you, Jim. Before we begin our Q&A session, I would like to take the opportunity to talk about a management transition noted in our press release. John Nebergall, our Chief Operating Officer, will step down from this position effective December 31. John will continue as a strategic advisor in 2024 as he relocates and travels the world. I want to thank John for his more than five years of service to the business. He was hired in mid-2018 to grow the business, focus the opportunity on the healthcare sector, and build out our management team. As part of that build-out, he hired Johnny Hecker, who will become our Chief Revenue Officer effective January 1, 2024, as well as the EVP of Operations. I would ask Johnny to join us now for the Q&A and I'll turn it over to the operator to instruct you how to queue for questions.

Thank you. We will now be conducting a question-and-answer session. We did have a question come from Jon Tanwanteng from CJS Securities. Jon, your line is live.

Hi. Good afternoon. It's Pete Lukas for Jon. I guess just in terms of the VA rollout, how much do you think you can gain from that plan next year on a gross revenue basis or however you want to define it? How should we think about that?

Yes, that's something we'd like to be able to know as well. As I mentioned in my opening remarks, although I gave some directional guidance for next year, it's clearly not the formal guidance nor is it a budget. As John noted in his comments, we had a very substantive meeting back in late August with not only Cognosante, the VA, and their various representatives. Here we sit in almost mid-November and there still is a plan being worked through in terms of exactly how the rollout will proceed. If I had to put it into two buckets the initial phase that we discussed last quarter concluded with the 40 sites, and the philosophy was that you would take each individual unit, call it a clinic, hospital, etc., and you would convert everything within that facility from what they were currently doing to ECFax. Now, that's not generally how we would roll out a large-scale corporate enterprise. What has occurred in this next phase that we have been rolling out is, and John noted this, we are rolling out more facilities but not necessarily taking all the pieces at a moment in time. This is an important distinction because there are layers of methods by which fax can be sent and received within an organization. To give you some idea, there are individual numbers, point-to-point communications, and fax that travels inbound versus outbound. Some may be on servers; some may be associated with multifunction devices, of which there could be a variety, think HP, Ricoh, Canon, Lexmark, Brother, etc. There are applications where you can fax the application or it can be received in. So it's a non-trivial exercise to think about taking an organization or an office and converting everything they do because likely they use all of these formats and converting them all. Typically, what we would do is go in order. The order would be generally how you can get the most users on a platform quickly and where there is the most concentration of traffic. As John noted in his remarks, there is an alignment here between the VA's objectives, Cognosante's objectives, and our objectives, which is more usage, more users, even if it's not necessarily a complete facility that transitions over at a moment in time. Having said that, we're still working through with Cognosante and the VA what that exactly means and what a rollout going forward looks like. So it's a lengthy answer to let you know that it's very much a work in progress. What we can say is that there's very little revenue in 2023 that we book to date and we are more likely to book in the remaining 50 days, 60 days of the year. So we do believe there will be a substantial uptick off a very small base in 2023. But even amongst ourselves, there's some range of what that number could be. My own belief and view is it should be seven digits, but where it is in the seven-digit range is very much a question I think yet to be answered. We will refine that number, and when we release our 2024 guidance in conjunction with the Q4 call, we'll have a more explicit view on that.

Very helpful. Thanks. I’ll jump back in the queue.

Okay. The next question is coming from Fatima Boolani from Citi. Fatima, your line is live.

Hey. Good afternoon, guys. This is Mark on for Fatima. Thanks for taking our questions. Maybe one for Johnny. I understand it's still early days – early in the process before you get into the CRO role. But when you take on the CRO role, any sort of early points you can share on your plans there? Should we maybe expect changes in sales incentives or go-to-market initiatives? And then any sort of color around areas of upside or downside risk as you're going to 2024 aside from the obvious macro headwinds? Thanks.

Thank you. Yes, good question. I think we've started that process earlier this year with the go-to-market realignment. I had the opportunity on the last earnings call to take everybody through our continuum of customers and how we are migrating our sales promotion to meet our customers on their buying motion to be more flexible in the market. I think we're going to continue on that road. As John mentioned in the remarks, we have started the e-commerce channel for the Corporate space. That's proven to be a successful program, so we're going to continue down that road. The one thing will definitely be that alignment with our customers' buying motion and continuing that realignment of our go-to-market sales and marketing teams. The other team will be obviously continuing to analyze our existing customer base and doubling down on the verticals that are most successful for us today, primarily that would be the healthcare space, right? We're seeing a lot of growth in that area. Scott talked about it in his opening remarks that it's more than 50% of our Corporate revenue by now, so we're going to continue down that road and double down on those verticals.

Great. Thank you. And then maybe just one for Scott or Jim. As you guys think going into 2024, any sort of guidance on capital allocation strategy or changes there? Could you see the optionality on the debt side but what's sort of the priority here given the macro headwinds?

Yes, we received a related question via email, but I'll respond to your question first, and then address that one as well. To update everyone who may not have been following the company since the spin, as I mentioned earlier, our options for capital allocation have been somewhat limited. We have primarily focused on investing in the company, repurchasing our equity, or engaging in M&A activities. We made a small acquisition early on by buying Summit, but that hasn’t been the main focus. Most of our capital has gone toward stock repurchases, which we have done consistently, along with accumulating cash. Now, our focus is shifting a bit since we have a maturity coming up in under three years for the 6% notes due on October 15, 2026, and two years later, the $500 million of 6.5% notes. After crossing the two-year mark since the spin, we now have the flexibility to buy back these securities. The 6.5% notes are non-callable, while the 6% notes are callable at $1.03. Due to interest rate changes, both securities are trading below par, although specific spot prices are less clear since the bonds are not as liquid as the stock. The 6.5% notes are currently in the mid-80s, while the nearer-term 6% notes are around the mid-90s. The Board has approved a $300 million repurchase program over the next three years, and I want to emphasize that this will be done opportunistically. So, we aren't going to make any immediate tender offers at a certain price. Instead, we will likely explore options in the open market, similar to our equity buyback approach. As we evaluate our cash reserves and prospective free cash flow, we intend to allocate a meaningful portion to debt retirement over time. I cannot specify the pace of our purchases yet or if they will happen in small increments or larger sums, especially since the maturity is three years away. We're aiming for the best possible deals on both securities and will be looking to acquire each tranche. I anticipate you will be asking about our quarterly purchases, which will be reflected in our reports. If we look at a two to three-year horizon, it’s likely to represent a significant portion of our cumulative cash balances, accumulating cash over the next few years. While we don't have to repay the 6% notes at maturity and cannot refinance, we are mindful that interest rates will likely be higher than they were when we issued the notes in late summer 2021. So, stay tuned to see the updates. Regarding the second question, it’s difficult to answer specifically about free cash flow for 2024. Currently, in 2023, we stand at $83 million for the first nine months, but Q4 is usually not a cash-generating quarter. We recently paid $25.5 million in interest on the two tranches of notes, and Q4 also includes estimated tax payments along with typical CapEx expenses. We will likely finish the year lower than $83 million, probably in the mid-$70 million range. Looking ahead, I'm uncertain about how much debt we will repurchase and the associated arbitrage since we are earning $540 million on our cash. Reducing the 6% and 6.5% coupon rates creates some gain, but the amount and timing of our buybacks remain unknown. As we approach next year, we expect to accumulate cash as we earn interest and pay taxes on it, and we could exceed the baseline if we manage to buy debt, thereby reducing a higher coupon and possibly acquiring at a discount. The most predictable change from 2023 to 2024 will be a reduction in capitalized labor costs, which we expect to decrease by at least $7 million year-over-year, directly benefiting our free cash flow. When we consider all these factors, we anticipate being in the low $80 million range next year, which we hope is a conservative estimate. We could perform better based on expected EBITDA growth and potential debt repurchases in the open market, which would give us additional leverage beyond just earning $540 million on cash.

Perfect. Thanks, Scott.

Thank you. And there were no other questions in queue at this time. I would now like to hand the call back to Scott Turicchi for closing remarks.

Great. Thank you, Paul, and thank you all for joining us today on our Q3 call. We will have the next earnings call, which of course will be the Q4 call. As I mentioned at the beginning, we will have a more robust discussion about 2024 guidance. That will be sometime in probably the latter part of February, third week of February 2024. We do have an upcoming High Yield Bond Conference at the end of this month, courtesy of Bank of America Merrill Lynch, and we'll be there. There will be another conference from BTIG that we'll be at on the 20th of November. That's for the equity holders, and then stay tuned for additional press releases for additional conferences probably more likely at the beginning of next year versus the balance of this year. Of course, if you have further questions, you can contact any one of us. We’d be happy to get back to you. Thank you.

Thank you. This does conclude today's conference. You may disconnect at this time and have a wonderful day. Thank you for your participation.